Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN363123 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Cas-Br-M (Murine) Ecotropic Retroviral Transforming Sequence (CBL) (AA 698-702) antibody
- Antibody type
- Polyclonal
- Antigen
- Peptide sequence around AA 698-702 (T-E-Y-M-T) derived from Human c-Cbl. Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates.
- Description
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography usingepitope-specific immunogen .
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 698-702
- Isotype
- IgG
- Vial size
- 50 μL
- Concentration
- 1 mg/mL
- Storage
- Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.
Submitted references Fas and Fas ligand interactions in malignant disease.
Nix and Nip3 form a subfamily of pro-apoptotic mitochondrial proteins.
c-Cbl: a regulator of T cell receptor-mediated signalling.
Identification and characterization of a human homolog of the Schizosaccharomyces pombe ras-like gene YPT-3.
Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LL
International journal of oncology 2000 Jul;17(1):5-12
International journal of oncology 2000 Jul;17(1):5-12
Nix and Nip3 form a subfamily of pro-apoptotic mitochondrial proteins.
Chen G, Cizeau J, Vande Velde C, Park JH, Bozek G, Bolton J, Shi L, Dubik D, Greenberg A
The Journal of biological chemistry 1999 Jan 1;274(1):7-10
The Journal of biological chemistry 1999 Jan 1;274(1):7-10
c-Cbl: a regulator of T cell receptor-mediated signalling.
Thien CB, Langdon WY
Immunology and cell biology 1998 Oct;76(5):473-82
Immunology and cell biology 1998 Oct;76(5):473-82
Identification and characterization of a human homolog of the Schizosaccharomyces pombe ras-like gene YPT-3.
Drivas GT, Shih A, Coutavas EE, D'Eustachio P, Rush MG
Oncogene 1991 Jan;6(1):3-9
Oncogene 1991 Jan;6(1):3-9
No comments: Submit comment
No validations: Submit validation data